Tune Therapeutics is a technology company.
Tune Therapeutics has raised $220.0M across 2 funding rounds.
Tune Therapeutics has raised $220.0M in total across 2 funding rounds.
Tune Therapeutics is a biotechnology company developing epi-therapeutic medicines via its proprietary TEMPO platform, which precisely tunes gene expression by modulating the epigenome without altering DNA sequences.[1][2][3] It targets complex diseases like cancer, genetic disorders, aging-related conditions, and chronic hepatitis B, serving patients with polygenic or multiplex diseases that traditional gene therapies cannot address.[1][2][4] The platform enables activation, silencing, or fine-tuning of gene networks to shift cell states toward healthy function, with early momentum shown in preclinical advances and a first-in-human clinical study for Tune-401 in chronic hepatitis B via a Novotech partnership.[2]
Launched publicly in December 2021 after stealth founding in 2020, Tune has raised significant funding from investors like New Enterprise Associates and Emerson Collective to advance its pipeline and leverage AI-driven workflows on AWS for rapid target discovery in liver diseases.[4][6] This positions Tune at the forefront of regenerative medicine, accelerating from lab discoveries to potential transformative therapies.[1][3]
Tune Therapeutics was founded in 2020 (formerly M2X2 Therapeutics) by world-leading researchers and venture-builders with expertise in gene therapy, genome editing, and epigenetics, based in Durham, NC, and Seattle, WA.[2][5][6] Key figures include CEO Matt Kane, who highlighted the epigenome as the true driver of health and disease, and co-founder Charlie Gersbach, acting chief scientific officer with a focus on extending genetic medicine beyond rare single-gene disorders.[1][4]
The idea emerged from breakthroughs in epigenomic understanding post-2010, including CRISPR advancements and high-throughput screening, enabling control over DNA packaging rather than editing the code itself.[3] Pivotal early traction came with the 2021 launch of the TEMPO platform, backed by a major funding round co-led by New Enterprise Associates and Emerson Collective, fueling preclinical research and talent acquisition.[1][4]
Tune stands out in genetic medicine through these key strengths:
Tune rides the epigenomics wave, shifting genetic medicine from DNA cuts (e.g., CRISPR) to reversible expression control amid rising demand for polygenic disease treatments.[1][3] Timing aligns with post-2020 breakthroughs in transcriptional modulation and iPSC tech, plus AI/biotech convergence for faster discovery—evident in Tune's AWS scaling.[3][6]
Market forces favor it: aging populations drive chronic disease needs, while regulatory progress (e.g., first-in-human epigenome editing trials) de-risks innovation.[2][4] Tune influences the ecosystem by pioneering "epi-therapeutics," inspiring a new modality for intractable conditions and partnering with CROs like Novotech to reach global patients.[2]
Tune is poised to advance TEMPO leads like Tune-401 through clinical milestones, expanding to oncology, genetic diseases, and regenerative applications with AI-accelerated pipelines.[2][6] Trends like epigenome mapping advances and combo therapies with CRISPR will amplify its edge, potentially evolving it into a biomedicine leader transforming common disease outcomes.[1][3]
This genetic tuning pioneer, born from epigenomic insights, could redefine medicine's frontiers just as it launched—with unbound potential now entering human proof.
Tune Therapeutics has raised $220.0M in total across 2 funding rounds.
Tune Therapeutics's investors include New Enterprise Associates, Versant Ventures.
Tune Therapeutics has raised $220.0M across 2 funding rounds. Most recently, it raised $180.0M Series B in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $180.0M Series B | New Enterprise Associates, Versant Ventures | |
| Dec 1, 2021 | $40.0M Series A | New Enterprise Associates, Versant Ventures |